Acute myeloid leukemia in adults.

Larry Cripe, S. Hinton

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m(2) as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, idarubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.

Original languageEnglish
Pages (from-to)9-17
Number of pages9
JournalCurrent Treatment Options in Oncology
Volume1
Issue number1
StatePublished - Apr 2000

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Idarubicin
Stem Cells
Clinical Trials
Transplants
Salvage Therapy
Mitoxantrone
Daunorubicin
Stem Cell Transplantation
Intravenous Infusions
Meta-Analysis
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Acute myeloid leukemia in adults. / Cripe, Larry; Hinton, S.

In: Current Treatment Options in Oncology, Vol. 1, No. 1, 04.2000, p. 9-17.

Research output: Contribution to journalArticle

@article{0b5ddb0255ba48aeb7074aa332ae278f,
title = "Acute myeloid leukemia in adults.",
abstract = "The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m(2) as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, idarubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.",
author = "Larry Cripe and S. Hinton",
year = "2000",
month = "4",
language = "English",
volume = "1",
pages = "9--17",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Acute myeloid leukemia in adults.

AU - Cripe, Larry

AU - Hinton, S.

PY - 2000/4

Y1 - 2000/4

N2 - The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m(2) as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, idarubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.

AB - The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m(2) as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, idarubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.

UR - http://www.scopus.com/inward/record.url?scp=0034174774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034174774&partnerID=8YFLogxK

M3 - Article

C2 - 12057057

AN - SCOPUS:0034174774

VL - 1

SP - 9

EP - 17

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -